Craft
Swedish Orphan Biovitrum

Swedish Orphan Biovitrum

Revenue

KR15.5 B

FY, 2021

Market Capitalization

KR67.8 B

2023-01-20

Swedish Orphan Biovitrum Summary

Company summary

Overview
Swedish Orphan Biovitrum (Sobi) is an integrated biotechnology company that researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The Company offers Elocta to treat haemophilia A, and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1, and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. Swedish Orphan Biovitrum manufactures drug substance for ReFacto AF, and develops BIVV001 and BIVV002 for the treatment of hemophilia. 
Type
Public
Status
Active
Founded
2001
HQ
Solna, SE | view all locations
Website
https://www.sobi.com/en
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Guido Oelkers

    Guido Oelkers, CEO

    • Håkan Björklund

      Håkan Björklund, Chairman

      • Torbjörn Hallberg

        Torbjörn Hallberg, General Counsel, Head of Legal Affairs and Head of HR

      • Henrik Stenqvist

        Henrik Stenqvist, CFO

        LocationsView all

        30 locations detected

        • Solna, Stockholms län HQ

          Sweden

          Tomtebodavägen 23a

        • Waltham, MA

          United States

          77 4th Ave 3rd Floor

        • Wien, Wien

          Austria

          Dorotheergasse 6/top 24

        • Zaventem, Vlaams Gewest

          Belgium

          Luchthaven Brussel Nationaal 1K 1930

        • Sofia, Sofia City Province

          Bulgaria

          46 - 48 opalchenska street

        • Oakville, ON

          Canada

          1155 North Service Rd West

        and 24 others

        Swedish Orphan Biovitrum Financials

        Summary financials

        Revenue (Q3, 2022)
        kr4.0B
        Gross profit (Q3, 2022)
        kr3.1B
        Net income (Q3, 2022)
        kr451.0M
        Cash (Q3, 2022)
        kr288.0M
        EBIT (Q3, 2022)
        kr699.0M
        Enterprise value
        $77.7B

        Blogs

        Footer menu